COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis

A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takasaki, Kazuki, Tsunenari, Takazumi, Mori, Kazuma, Aochi, Satsuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634247/
https://www.ncbi.nlm.nih.gov/pubmed/34848425
http://dx.doi.org/10.1136/bcr-2021-246700
_version_ 1784608095201132544
author Takasaki, Kazuki
Tsunenari, Takazumi
Mori, Kazuma
Aochi, Satsuki
author_facet Takasaki, Kazuki
Tsunenari, Takazumi
Mori, Kazuma
Aochi, Satsuki
author_sort Takasaki, Kazuki
collection PubMed
description A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxis was added. With these treatments, the patient has made a good recovery, and he was discharged on hospital day 11. There is no standard strategy for prophylaxis of thrombosis in patients with ET, and apixaban could be a clinical benefit for these patients.
format Online
Article
Text
id pubmed-8634247
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86342472021-12-10 COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis Takasaki, Kazuki Tsunenari, Takazumi Mori, Kazuma Aochi, Satsuki BMJ Case Rep Case Report A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxis was added. With these treatments, the patient has made a good recovery, and he was discharged on hospital day 11. There is no standard strategy for prophylaxis of thrombosis in patients with ET, and apixaban could be a clinical benefit for these patients. BMJ Publishing Group 2021-11-30 /pmc/articles/PMC8634247/ /pubmed/34848425 http://dx.doi.org/10.1136/bcr-2021-246700 Text en © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
spellingShingle Case Report
Takasaki, Kazuki
Tsunenari, Takazumi
Mori, Kazuma
Aochi, Satsuki
COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
title COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
title_full COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
title_fullStr COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
title_full_unstemmed COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
title_short COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
title_sort covid-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634247/
https://www.ncbi.nlm.nih.gov/pubmed/34848425
http://dx.doi.org/10.1136/bcr-2021-246700
work_keys_str_mv AT takasakikazuki covid19withessentialthrombocythemiatreatedwithapixabanforantithromboticprophylaxis
AT tsunenaritakazumi covid19withessentialthrombocythemiatreatedwithapixabanforantithromboticprophylaxis
AT morikazuma covid19withessentialthrombocythemiatreatedwithapixabanforantithromboticprophylaxis
AT aochisatsuki covid19withessentialthrombocythemiatreatedwithapixabanforantithromboticprophylaxis

Ejemplares similares